Ulcerative Colitis: The Complete Guide to Medical Management

Gary R. Lichtenstein, MD, FACP, FACG, AGAF

Chapter 24: Novel Biological Agents for the Treatment of Ulcerative Colitis (continued)

Gert Van Assche, MD, PhD, FRCP; Paul Rutgeerts, MD, PhD, FRCP

NOVEL BIOLOGICAL AGENTS FOR THE TREATMENT OF ULCERATIVE COLITIS Despite the therapeutic efficacy of the biological agent infliximab in Crohn’s disease (CD), the development of agents specifically interacting with an immune pathway has not led to registered novel therapeutics in ulcerative colitis (UC). Recently, more biological agents have entered development programs in this indication (Table 24-1), but (contrary to the situation in CD) many of these programs have originally been driven by interest from investigators involved in patient care and not by the pharmaceutical industry…